Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

CEO Bids to Take Tongjitang Private

publication date: Mar 10, 2008

Tongjitang Chinese Medicines Company received a buy-out offer from its Chairman and CEO, Mr. Xiaochun Wang, for $10.20 per ADS, a 55% premium to its closing price on Friday of $6.60 per ADS. Tongjitang makes modernized forms of traditional Chinese medicines. Tongjitang made its IPO in March of 2007 at $10 per ADS. It has traded as high as $12.88, but the recent downtrend in stock markets took the stock price to new lows. More details...

Stock Symbol: (NYSE: TCM)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital